Found 285 articles for: "biologics"
COVID-19 Vaccine and Biologics: An Impending Dilemma
January 2021 | Volume 20 | Issue 1 | Editorials | 115 | Copyright © January 2021
The COVID-19 pandemic has forced healthcare providers across all specialties to adjust their methods of clinical practice. I...
Read MoreMetformin as Adjunctive Therapy for Pediatric Patients With Hidradenitis Suppurativa
December 2020 | Volume 19 | Issue 12 | Original Article | 1231 | Copyright © December 2020
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disorder seen in adolescents and adults characterized by abscesses, sinus tracts and scarring, typically affecting ...
Read MoreUveitis for Dermatologists: A Review
December 2020 | Volume 19 | Issue 12 | Original Article | 1192 | Copyright © December 2020
Certain dermatologic conditions and drugs used for their treatment are associated with uveitis, a vision-threatening group of inflammatory eye diseases. Dermatologists may therefore be the first healt...
Read MoreApremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis
December 2020 | Volume 19 | Issue 12 | Original Article | 1149 | Copyright © December 2020
Background: About 20% of patients taking apremilast alone obtain PASI 75 by week 8. This single-center, pilot study aimed to determine whether add-on topical therapy with calcipotrien...
Read MorePredicting Secukinumab Fast-Responder Profile in Psoriatic Patients: Advanced Application of Artificial-Neural-Networks (ANNs)
December 2020 | Volume 19 | Issue 12 | Editorials | 1241 | Copyright © December 2020
Background: Drug resistance to biologics in psoriasis therapy can occur – it may be acquired during a treatment or else present itself from the beginning. To date, no biomarkers...
Read MoreTherapies for Psoriasis: Clinical and Economic Comparisons
November 2020 | Volume 19 | Issue 11 | Original Article | 1101 | Copyright © November 2020
Background: Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new devel- opment in the field. With the recent availability of a ...
Read MoreGeographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis Registry
November 2020 | Volume 19 | Issue 11 | Editorials | 1119 | Copyright © November 2020
Is TNF-α Inhibitor-Induced Psoriasiform Dermatitis Always Psoriasiform?
October 2020 | Volume 19 | Issue 10 | Features | 1009 | Copyright © October 2020
Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience
October 2020 | Volume 19 | Issue 10 | Original Article | 978 | Copyright © October 2020
Background and Objectives: Patients with the rare disease hereditary angioedema (HAE) suffer from recurrent acute attacks of edema. There is no curative therapy, but the frequency of ...
Read MoreEfficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis
September 2020 | Volume 19 | Issue 9 | Original Article | 874 | Copyright © September 2020
Objective: To demonstrate the efficacy and safety of adding fixed-dose combination calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) foam to oral apremilast in trea...
Read MoreFixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication
August 2020 | Volume 19 | Issue 8 | Original Article | 723 | Copyright © August 2020
Calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam is a topical agent indicated for the treatment of plaque psoriasis. While topical treatments are typically reserved fo...
Read MoreHalobetasol Propionate Lotion 0.01% for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis in Male and Female Participants
August 2020 | Volume 19 | Issue 8 | Original Article | 747 | Copyright © August 2020
Introduction: Psoriasis is a chronic, immune-mediated skin disease that is associated with sex-related differences. Two double-blind, vehicle-controlled, phase 3 studies evaluated hal...
Read MoreThe Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
August 2020 | Volume 19 | Issue 8 | Original Article | 703 | Copyright © August 2020
Background: Metabolic syndrome (MetS) is the most prevalent comorbidity in psoriasis and increases the risk of cardiovasc...
Read MoreSafety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies Errata
June 2020 | Volume 19 | Issue 6 | Editorials | 573 | Copyright © June 2020
Erratum for article "Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies." Retriev...
Read MoreSafety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata
June 2020 | Volume 19 | Issue 6 | Editorials | 571 | Copyright © June 2020
Erratum for article "Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)." Retrieved from Read More
Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis (Errata)
June 2020 | Volume 19 | Issue 6 | Editorials | 566 | Copyright © June 2020
Erratum for "Evaluation of Risk of Major Adverse Cardiovascular Events with Biologic Therapy in Patients with Psoriasis." Read More
The New Psoriasis Paradigm: Striving for Complete Clearance
June 2020 | Volume 19 | Issue 6 | Original Article | 652 | Copyright © June 2020
Newer biologics have introduced the possibility of higher and more complete clearance rates than previously possible. For many patients, PASI 90 and PASI 100 responses are realistic. Furthermore, high...
Read MoreBiologics and Small Molecules in the Treatment of COVID-19
June 2020 | Volume 19 | Issue 6 | Features | 673 | Copyright © June 2020
Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females
May 2020 | Volume 19 | Issue 5 | Original Article | 504 | Copyright © May 2020
Background: Previous results from two phase 3 studies demonstrated efficacy and safety of fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in participa...
Read MoreImportance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes
May 2020 | Volume 19 | Issue 5 | Original Article | 487 | Copyright © May 2020
Psoriasis is associated with physical, psychological, social, and economic burdens that lead to substantial impairment over a patient&rsqu...
Read More